Cisen Pharmaceutical Co., Ltd.

Quinolone antibiotics have antibacterial effects on Gram-negative bacteria and some Gram-positive cocci, and have a bactericidal effect by inhibiting bacterial DNA gyrase.

This product is a quinolone antibacterial drug, which has strong antibacterial effect on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effect on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

This product is a fluoroquinolone antibacterial drug, which has strong antibacterial effects on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effects on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. The mechanism of action of this product is to kill bacteria by inhibiting bacterial DNA gyrase.

By inhibiting phosphodiesterase and activating adenylate cyclase, intracellular cAMP increases, the formation and release of prostaglandins are promoted, the vascular smooth muscle of the arteriolar wall is relaxed, platelet aggregation is inhibited, and partial disaggregation of aggregated platelets is promoted; by increasing the intracellular ATP content, red blood cell stiffness is reduced, and red blood cell deformability is improved; red blood cell aggregation is inhibited; and blood viscosity is reduced, blood flow is promoted, and circulation and nutrition of hypoxic tissues are improved.

It is a cell cycle-specific antitumor drug that inhibits the polymerization of intracellular tubulin, prevents the formation of spindles in the mitosis of proliferating cells, and stops cell division at the metaphase of mitosis. This product has a broad antitumor spectrum for transplanted animal tumors and has no complete cross-resistance with vinblastine and vincristine.